Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kinect

- PMLiVE

Novartis faces criticism over Zolgensma ‘health lottery’

SMA Europe deems access programme 'inappropriate'

Novartis day

Cosentyx, Entresto drive topline growth for Novartis in Q4

Overall net income fell for the full year compared to 2018

- PMLiVE

A snapshot of Congenica

PME talks to CEO David Atkins

- PMLiVE

The digital shift in pharma marketing

Indegene’s surveys in 2016 and 2019 show a spike in digital spend

- PMLiVE

Novartis gets EU approval for multiple sclerosis therapy Mayzent

Offers subgroup of patients an important new treatment option

- PMLiVE

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Outperformed rival across all primary and secondary endpoints

- PMLiVE

Novartis links up with NHS for speedy access to cholesterol drug inclisiran

Collaboration will see drug offered to patients across the UK via clinical study

- PMLiVE

Novartis reveals positive efficacy data for Xolair follow-up

Next-generation treatment is more effective than current therapy

- PMLiVE

Novartis picks up inclisiran after completion of MedCo acquisition

If approved could become blockbuster cholesterol treatment

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Novartis ditches oral asthma drug after disappointing phase 3 readout

Bad news for Gossamer’s would-be rival DP2 antagonist

- PMLiVE

Intec battered as Novartis ducks out of Accordion collaboration

Shares fell by more than 12% after the annoucement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links